c-Jun knockdown sensitizes osteosarcoma to doxorubicin

Download

Full text for this resource is not available from the Research Repository.

Export

Dass, Crispin R, Khachigian, Levon M and Choong, Peter F. M (2008) c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Molecular Cancer Therapeutics, 7 (7). pp. 1909-1912. ISSN 1535-7163

Abstract

The oncogene c-Jun has been found to be up-regulated in a variety of cancers, including osteosarcoma. Doxorubicin is a frontline chemotherapeutic against osteosarcoma, but is limited by toxicity. DNAzymes are oligonucleotides capable of specific catalysis of target mRNA. A biocompatible c-Jun DNAzyme nanoparticle formulated from chitosan regressed the growth and metastasis of preestablished tumors, especially in combination with doxorubicin. In vitro data confirmed that c-Jun knockdown chemosensitized these cells to doxorubicin treatment. c-Jun down-regulation–mediated tumor inhibition also led to concomitant decreased osteolysis. Clinically, knockdown of c-Jun with chitosan nanobiotechnology may proffer an improved treatment outcome for osteosarcoma.

Dimensions Badge

Altmetric Badge

Item type	Article
URI	https://vuir.vu.edu.au/id/eprint/3599
DOI	10.1158/1535-7163.MCT-08-0086
Official URL	http://mct.aacrjournals.org/content/7/7.toc
Subjects	Historical > RFCD Classification > 320000 Medical and Health Sciences Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences Historical > FOR Classification > 1117 Public Health and Health Services
Keywords	ResPubID18862. c-Jun, osteosarcoma, doxorubicin, DNAzymes, tumors, mRNA, chitosan, bone, cancer
Citations in Scopus	32 - View on Scopus
Download/View statistics	View download statistics for this item